Martine Piccart

1982–2025 年に発表

331
論文数
97,181
被引用数
145
h 指数
325
i10 指数

被引用数

Martine Piccart の年別被引用数1971 年: 被引用 1 件1974 年: 被引用 2 件1981 年: 被引用 2 件1982 年: 被引用 1 件1983 年: 被引用 1 件1984 年: 被引用 2 件1985 年: 被引用 1 件1986 年: 被引用 1 件1987 年: 被引用 1 件1988 年: 被引用 3 件1989 年: 被引用 2 件1990 年: 被引用 2 件1991 年: 被引用 2 件1992 年: 被引用 2 件1993 年: 被引用 4 件1994 年: 被引用 4 件1995 年: 被引用 4 件1996 年: 被引用 21 件1997 年: 被引用 17 件1998 年: 被引用 23 件1999 年: 被引用 16 件2000 年: 被引用 38 件2001 年: 被引用 59 件2002 年: 被引用 61 件2003 年: 被引用 102 件2004 年: 被引用 92 件2005 年: 被引用 143 件2006 年: 被引用 266 件2007 年: 被引用 386 件2008 年: 被引用 545 件2009 年: 被引用 559 件2010 年: 被引用 688 件2011 年: 被引用 628 件2012 年: 被引用 647 件2013 年: 被引用 739 件2014 年: 被引用 771 件2015 年: 被引用 925 件2016 年: 被引用 1,013 件2017 年: 被引用 988 件2018 年: 被引用 873 件2019 年: 被引用 2,956 件2020 年: 被引用 3,366 件2021 年: 被引用 3,343 件2022 年: 被引用 2,852 件2023 年: 被引用 2,260 件2024 年: 被引用 3,617 件2025 年: 被引用 1,604 件2026 年: 被引用 61 件1972〜1973 年は被引用が無いため表示していません1975〜1980 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 7,626 件、この内訳の 21.6%中国: 引用元論文 3,679 件、この内訳の 10.4%イタリア: 引用元論文 2,237 件、この内訳の 6.3%イギリス: 引用元論文 2,182 件、この内訳の 6.2%ドイツ: 引用元論文 1,686 件、この内訳の 4.8%フランス: 引用元論文 1,549 件、この内訳の 4.4%カナダ: 引用元論文 1,245 件、この内訳の 3.5%スペイン: 引用元論文 1,218 件、この内訳の 3.5%ベルギー: 引用元論文 1,115 件、この内訳の 3.2%オランダ: 引用元論文 1,057 件、この内訳の 3%スイス: 引用元論文 987 件、この内訳の 2.8%オーストラリア: 引用元論文 923 件、この内訳の 2.6%
0%21.6%その他 27.7%

分野

  • Medicine52.9%
  • Biochemistry, Genetics and Molecular Biology37.7%
  • Immunology and Microbiology2.9%
  • Computer Science1.8%
  • Materials Science1%
  • Engineering0.8%
  • その他2.9%

トピック

  • Breast Cancer Treatment Studies8.3%
  • HER2/EGFR in Cancer Research6.3%
  • Cancer Immunotherapy and Biomarkers4.1%
  • Advanced Breast Cancer Therapies4%
  • Cancer Genomics and Diagnostics2.9%
  • Cancer Cells and Metastasis2.9%
  • その他71.5%

共著者

全論文

検索で開く
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2021 被引用: 1,543

  2. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bernd Gerber, Charles E. Geyer, Richard Pazdur, Nina Ditsch, Priya Rastogi, W. Eiermann, Gϋnter von Minckwitz - The Lancet 2014 被引用: 4,710

  3. Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Joseph P. Costantino, Amal Arahmani, Norman Wolmark, Eleanor McFadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer - New England Journal of Medicine 2021 被引用: 1,665

  4. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Sibylle Loibl, Monica Morrow, Moïse Namer, C. Kent Osborne, Ann H. Partridge, Frédérique Penault‐Llorca, Charles M. Perou, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Michael Untch, Giuseppe Viale, Toru Watanabe, Nicholas Wilcken, Eric P. Winer, William C. Wood - Annals of Oncology 2013 被引用: 3,715

  5. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer - Annals of Oncology 2016 被引用: 2,062

  6. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Viviana Galimberti, Hebatallah Gamal El Din Mohamed Mahmoud, Judy E. Garber, Michael Gnant, William J. Gradishar, Bahadır M. Güllüoğlu, Nadia Harbeck, Chiun‐Sheng Huang, Jens Huober, André Ilbawi, Zefei Jiang, Steven Johnston, Eun Sook Lee, Sibylle Loibl, Monica Morrow, Ann H. Partridge, Martine Piccart, Philip Poortmans, Aleix Prat, Meredith M. Regan, Isabella Rubio, Hope S. Rugo, Emiel J. Rutgers, Felix Sedlmayer, Vladimir Semiglazov, Hans-Joerg Senn, Zhiming Shao, Tanja Španić, Petra Tesařová, Beat Thürlimann, Sergei Tjulandin, Masakazu Toi, Maureen Trudeau, Nicholas Turner, Inez Vaz Luis, Giuseppe Viale, Toru Watanabe, William P. Weber, Eric P. Winer, Binghe Xu - Annals of Oncology 2021 被引用: 803

  7. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , René Bernards, Konstantinos Tryfonidis, Emiel J. Rutgers, Martine Piccart - New England Journal of Medicine 2016 被引用: 2,051

  8. Immunotherapy in breast cancer: an overview of current strategies and perspectives

    著者: , , , , , , - npj Breast Cancer 2023 被引用: 355

  9. CD4+ follicular helper T cell infiltration predicts breast cancer survival

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2013 被引用: 1,050

  10. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2011 被引用: 2,828

  11. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke ほか 509 名 - Annals of Oncology 2022 被引用: 447

  12. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz ほか 10 名 - The Lancet Oncology 2017 被引用: 1,133

  13. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2017 被引用: 1,399

  14. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers

    著者: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 891

  15. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mirko Dolci, Richard D. Gelber - New England Journal of Medicine 2005 被引用: 5,098

  16. Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

    著者: , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2013 被引用: 1,647

  17. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer

    著者: , , , , , , , - British Journal of Cancer 2019 被引用: 293

  18. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Clifford A. Hudis, James N. Ingle, Jacek Jassem, Zefei Jiang, Per Karlsson, Monica Morrow, Roberto Orecchia, C. Kent Osborne, Ann H. Partridge, Lorena de la Peña, Martine Piccart, Kathleen I. Pritchard, Emiel J. Rutgers, Felix Sedlmayer, Semiglazov Vf, Zhi‐Ming Shao, Ian Smith, Beat Thürlimann, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Gϋnter von Minckwitz, Toru Watanabe, Timothy J. Whelan, Eric P. Winer, Binghe Xu - Annals of Oncology 2015 被引用: 1,837

  19. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet 2017 被引用: 1,041

  20. Clinical management of breast cancer heterogeneity

    著者: , , , - Nature Reviews Clinical Oncology 2015 被引用: 567

  21. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial

    著者: , , , , , , , , , , , , , , , - Annals of Oncology 2014 被引用: 1,270

  22. ESMO-Magnitude of Clinical Benefit Scale version 1.1

    著者: , , , , , , , , , - Annals of Oncology 2017 被引用: 648

  23. Tumor-infiltrating B cells signal functional humoral immune responses in breast cancer

    著者: , , , , , , , , , , , , , , , , - JCI Insight 2019 被引用: 350

  24. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 被引用: 359